Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

venues and earnings

The Group's revenues are partly dependent on the level of reimbursement provided to the Group by governmental reimbursement schemes for pharmaceutical products. Changes to governmental policy or practices could adversely affect the Group's sales, financial condition and results of operations. In addition, the cost of treatment established by health care providers, private health insurers and other organizations, such as health maintenance organizations and managed care organizations are under downward pressure and this, in turn, could impact on the prices at which the Group can sell its products.

The market for pharmaceutical products could be significantly influenced by the following, which could result in lower prices for the Group's products and/or a reduced demand for the Group's products:

    - the ongoing trend toward managed health care, particularly in
      the US;

    - legislative proposals to reform health care and government
      insurance programs in many of the Group's markets; and

    - price controls and non-reimbursement of new and highly priced
      medicines for which the economic and therapeutic rationales are not
      established.

The prices for certain of the Group's products when commercialized, in particular products for the treatment of rare genetic diseases such as REPLAGAL and ELAPRASE, may be high compared to other pharmaceutical products. The Group may encounter particular difficulty in obtaining satisfactory pricing and reimbursement for its products, including those that are likely to have a high annual cost of therapy. The failure to obtain and maintain pricing and reimbursement at satisfactory levels for such products may adversely affect revenues and earnings.

Parallel importation occurs when an importer finds a cheaper price for a product or equivalent product on the world market and imports that product f
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... YORK , Aug. 27, 2014 Guggenheim ... Guggenheim Partners, today announced the hiring of veteran equity ... senior equity analyst. Mr. Butler will focus on the ... our team a wealth of experience and a broad ... Ferrarie , Senior Managing Director and Head of Equities ...
(Date:8/27/2014)... 27, 2014 Research and Markets ... for Pulp & Paper Industry Report 2014" report ... for Pulp & Paper Industry Report 2014 is a ... the global enzyme for pulp & paper industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, ... delivery technologies, today announced that it has been selected ... & Industry Association,s 2014 Awards for Excellence ... by an independent panel of judges from SCORE (Counselors ... Award winners will be honored at a gala event ...
(Date:8/27/2014)... OR (PRWEB) August 27, 2014 After ... to reason that the next beverage craze is going ... announced today that formulators can use Stress Relief energy ... used in the making of a beverage, including minerals, ... for stress-generated energy, channeling that power into rapid recovery ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... Company now officially following an FDA 510(k) (Pre-Market Notification), Pathway for ... ... Human Appendicitis, CASTLE ROCK, Colo., Nov. 27 AspenBio Pharma,Inc. ... of novel drugs and diagnostics for animals and humans, has,received an ...
... Shamir,Optical Industry Ltd. (Nasdaq: SHMR ) ("Shamir"), a ... ophthalmic lens,market, today announced unaudited financial results for the ... ended September 30, 2007, revenues increased by 28.5%,to $30.9 ... of 2006.,Gross profit for the quarter increased by 25.3% ...
... Masimo receives approval from Ministry of Health, Labor and Welfare ... carbon ... monoxide levels in the blood, IRVINE, Calif., ... Motion and Low Perfusion pulse,oximetry, today announced approval of the ...
Cached Biology Technology:AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 2Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 3Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 5Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 6Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 7Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 8Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 9Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 10Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 3Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 4
(Date:8/27/2014)... that a single fungal cell or bacterial colony exerts on ... a heavy role in setting up some of the most ... be too much of a stretch to say that plants ... respond to the touch of beneficial fungi, according to a ... at the University of Wisconsin-Madison. , "Many people have ...
(Date:8/27/2014)... 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced ... offering of units of common stock and warrants at ... of $20 million, prior to deducting underwriting discounts and ... shares and warrants are immediately separable and will be ... the offering consists of 2,000 shares of common stock ...
(Date:8/27/2014)... bears, giant ground sloths, saber-toothed cats and American camels ... at the end of the Pleistocene period. The cause ... scientists who, until recently, could only speculate as to ... Barbara,s James Kennett, professor emeritus in the Department of ... played a major role in the extinction. Their hypothesis ...
Breaking Biology News(10 mins):A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... everyone will see the light and start living more ... may be doing more harm than good. So ... a provocative essay in the March 2009 issue of ... Vucetich, assistant professor of animal ecology at Michigan Technological ...
... New York, NY) The Parkinson,s Disease Foundation (PDF) has ... Parkinson,s disease scientists. The grants will sustain promising ... sudden collapse of their primary private funder, The Picower ... by Bernard Madoff, was forced to cease all grantmaking ...
... scientists is renewing calls for policymakers to reduce both ... or nutrient pollution problems in fresh and coastal ... , the researchers argue that dual-nutrient reduction strategies are ... between nitrogen and phosphorus in fresh and coastal water ...
Cached Biology News:Abandon hope 2Parkinson's Disease Foundation awards $300,000 in bridge funding for innovative research projects 2Parkinson's Disease Foundation awards $300,000 in bridge funding for innovative research projects 3
MAb to Vasopressin Preservative: NaN3...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Biology Products: